Table 1.
Acalabrutinib (ACP-196) for hematological malignancies
| Agents | Diseases | Phase | NCT |
|---|---|---|---|
| ACP-196 Dexamethasone |
MM | Phase 1 | NCT02211014 |
| ACP-196 | ABC DLBCL | Phase 1 | NCT02112526 |
| ACP-196 Rituximab (IV) |
FL | Phase 1 | NCT02180711 |
| ACP-196 Obinutuzumab |
CLL, SLL, PLL | Phase 1 | NCT02296918 |
| ACP-196 ACP-319 |
CLL | Phase 1 | NCT02157324 |
| ACP-196 ACP-319 |
NHL, MM, B-All | Phase 1/2 | NCT02328014 |
| ACP-196 | WM | Phase 1/2 | NCT02180724 |
| ACP-196 | CLL, SLL, RS, PLL | Phase 1/2 | NCT02029443 |
| ACP-196 Pembrolizumab |
NHL, MM, HL, CLL, RS, WM, Myelofibrosis | Phase 1/2 | NCT02362035 |
| ACP-196 | CLL, SLL | Phase 2 | NCT02337829 |
| ACP-196 | MCL | Phase 2 | NCT02213926 |
| ACP-196 Obinutuzumab Chlorambucil |
CLL | Phase 3 | NCT02475681 |
| ACP-196 Ibrutinib |
CLL | Phase 3 | NCT02477696 |
NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, MCL mantle cell lymphoma, FL follicular lymphoma, ABC DLBCL activated B cell diffuse large B cell lymphoma, CLL chronic lymphocytic leukemia, SLL small lymphocytic lymphoma, WM Waldenstrom’s macroglobulinemia, RS Richter’s syndrome, PLL prolymphocytic leukemia